




PERIMETER

Imaging Like You've Never Seen Before

Weekly IR Round-Up

Accelerating the Learning Curve for Customers

Click on the video below and take a look at this OCT image of a lumpectomy margin. Do you notice the circular shaped feature traveling through the fibrous tissue? That's a suspicious duct, which correlated to the post-op pathology report confirming Ductal carcinoma in situ, or DCIS, at the margin.



Typically, we find that the learning curve for surgeons and clinicians is relatively fast, supported by image interpretation training, an exclusive Imaging Atlas reference library with pathology-verified tissue structure correlations, as well as "in-OR" support from Perimeter's field-based [Clinical Education team](#).

The Patient Journey


We understand that every patient's treatment and healing journey is unique as they move beyond surgery and get back to doing things they love.

Listen to Nadia as she shares her journey with breast cancer and infertility, as well as her treatment plan that included Perimeter's technology:



AI Webinar Series

Did you tune into our recent [AI webinar](#) featuring a discussion with Perimeter Board member, Anantha Kancherla (former head of Meta's AI platform) and Perimeter's CEO, Adrian Mendes? [Let us know if you have any follow-up questions or other AI topics of interest](#), and we will integrate them into future AI webinars in the series!



Let's Stay Connected

Follow Perimeter Medical on Social!

The best way to hear the latest news from Perimeter is to follow us on one of our social media channels:

- [X](https://twitter.com/PerimeterMed) (formerly Twitter): <https://twitter.com/PerimeterMed>

- **LinkedIn:** <https://www.linkedin.com/company/perimeter-medical-imaging/>

You can also sign up to get Perimeter [news release alerts](#) delivered directly to your email or check out the news feed on our [investor website](#).

Perimeter S-Series OCT has 510(k) clearance under a general indication and has not been evaluated by the U.S. FDA specifically for use in breast tissue, breast cancer, other types of cancer, margin evaluation, and reducing re-excision rates. The safety and effectiveness of these uses has not been established. For more information, please visit www.perimetermed.com/disclosures.

For more information about Perimeter, please contact: investors@perimetermed.com



Perimeter Medical Imaging AI, 8585 N. Stemmons Freeway, Suite 106N, Dallas, TX 75247

[Unsubscribe Preferences](#)

[TSXV: PINK](#) | [OTC PYNKF](#) | [FSE: 4PC](#)



© 2024 Perimeter Medical Imaging AI, Inc.